• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
GID
Click for more information
0.00% 0.2¢

GI DYNAMICS, INC - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
GID Trading HaltPRICE SENSITIVE05/03/15
GID Preliminary Final ReportPRICE SENSITIVE27/02/15
GID Appendix 3B11/02/15
GID Executive Separation Agreement03/02/15
GID Appendix 4C - quarterlyPRICE SENSITIVE30/01/15
GID Appendix 3B19/01/15
GID Corporate Restructuring and Departure of CFOPRICE SENSITIVE09/12/14
GID GI Dynamics Resumes Shipments of EndoBarrier ProductPRICE SENSITIVE01/12/14
GID GI Dynamics to Present at the Piper Jaffray Healthcare Conf19/11/14
GID Appendix 3B14/11/14
GID Registration Statement on Form S-8 Filed with SEC13/11/14
GID Results of Special Meeting of Stockholders12/11/14
GID Form 10-Q Filed for 3rd Quarter 2014 with SECPRICE SENSITIVE11/11/14
GID Final Director's Interest Notice05/11/14
GID Director Appointment/Resignation05/11/14
GID Change of Director's Interest Notice31/10/14
GID Appendix 4C - quarterlyPRICE SENSITIVE31/10/14
GID Notice of Extraordinary General Meeting/Proxy Form30/10/14
GID Application for Listing on NASDAQ Capital Market28/10/14
GID Briefing Call and Webcast on Financial Results for Q3 201428/10/14
GID Notice of Extraordinary General Meeting/Proxy Form23/10/14
GID +Change in substantial holding from HHL14/10/14
GID GI Dynamics Suspends Shipments of CE Marked ProductPRICE SENSITIVE06/10/14
GID Trading HaltPRICE SENSITIVE06/10/14
GID Initial Director's Interest Notice19/09/14
GID Appendix 3B19/09/14
GID New Clinical Data on EndoBarrier Therapy Presented at EASDPRICE SENSITIVE18/09/14
GID Appendix 3B17/09/14
GID Change of Director's Interest Notice15/09/14
GID Initial Director's Interest Notice12/09/14
GID GI Dynamics Appoints Daniel Moore to the Board of Directors11/09/14
GID Clinical Data on EndoBarrier Therapy to be Presented at EASD09/09/14
GID New Clinical Data on EndoBarrier Therapy Presented at IFSO29/08/14
GID Appointment of Michael Dale as President & CEOPRICE SENSITIVE29/08/14
GID Half Yearly Report and AccountsPRICE SENSITIVE15/08/14
GID Appendix 3B14/08/14
GID +Change in substantial holding from HHL07/08/14
GID Appendix 4C - quarterlyPRICE SENSITIVE31/07/14
GID Launch of EndoBarrier Therapy Clinical Study in FrancePRICE SENSITIVE30/07/14
GID Effectiveness of U.S. SEC Form 10 Registration Statement21/07/14
GID Briefing Call and Webcast on Financial Results for Q2 201421/07/14
GID Appendix 3B10/07/14
GID Departure of CCO & Update on 2nd Quarter RevenuesPRICE SENSITIVE02/07/14
GID +Becoming a substantial holder from HHL - corrected20/06/14
GID +Becoming a substantial holder from HHL19/06/14
GID New EndoBarrier data presented at ADA meetingPRICE SENSITIVE16/06/14
GID New EndoBarrier data to be presented at ADA meeting10/06/14
GIDChange of Director's Interest Notice04/06/14
GIDAppendix 3B04/06/14
GIDResults of Meeting22/05/14
GIDAnnual General Meeting - Withdrawal of Resolution 320/05/14
GIDReduced Reliance on Insulin by Patients with EndoBarrierPRICE SENSITIVE16/05/14
GID2014 Annual Meeting of Stockholders Webcast and Call15/05/14
GIDBecoming a substantial holder - CORRECTION13/05/14
GIDBecoming a substantial holder13/05/14
GIDCeasing to be a substantial holder - CORRECTION12/05/14
GIDTwo New Centres Offer EndoBarrier in Australia12/05/14
GIDForm604 Notice of change of interests of substantial holder12/05/14
GIDCeasing to be a substantial holder09/05/14
GIDChange in substantial holding09/05/14
GIDChange in substantial holding09/05/14
GIDChange in substantial holding09/05/14
GIDChange in substantial holding09/05/14
GIDASX 3.10.5A announcement09/05/14
GIDCleansing Notice09/05/14
GIDAppendix 3B09/05/14
GIDEndoBarrier Data from Research with GSK Presented at DDWPRICE SENSITIVE06/05/14
GIDGI Dynamics Completes A$34.3 Million Private PlacementPRICE SENSITIVE02/05/14
GIDGI Dynamics to Present at the Deutsche Bank Healthcare Conf01/05/14
GIDForm 10 Filed with U.S. Securities and Exchange Commission01/05/14
GIDNotice of Annual General Meeting/Proxy Form30/04/14
GIDTrading HaltPRICE SENSITIVE30/04/14
GIDAppendix 4C - quarterlyPRICE SENSITIVE29/04/14
GIDNew EndoBarrier Data to be Presented at Medical Meetings29/04/14
GIDBriefing Call and Webcast on Financial Results for Q1 201415/04/14
GIDEndoBarrier Receives Reimbursement Coverage in IsraelPRICE SENSITIVE07/04/14
GIDExpands Availability of EndoBarrier Therapy in AustraliaPRICE SENSITIVE01/04/14
GIDAnnual Report to shareholders31/03/14
GIDAppendix 3B27/03/14
GIDPreliminary Reimbursement Coverage in the NetherlandsPRICE SENSITIVE27/03/14
GIDAppendix 3B21/03/14
GIDAppendix 3B12/03/14
AAI +S&P DJ Indices Announces March Quarterly Rebalance07/03/14
GIDPreliminary Final ReportPRICE SENSITIVE28/02/14
GIDAppendix 3B04/02/14
GIDExpanded Reimbursement Coverage in GermanyPRICE SENSITIVE03/02/14
GIDAppendix 4C - quarterlyPRICE SENSITIVE31/01/14
GIDBriefing Call and Webcast on Financial Results for Q4 201321/01/14
GIDNew Meta-Analysis Further Demonstrates Safety and EfficacyPRICE SENSITIVE03/12/13
GIDAppendix 3B20/11/13
GIDAppendix 4C - quarterlyPRICE SENSITIVE31/10/13
GIDChange in substantial holding29/10/13
GIDAppendix 3B17/10/13
GIDOPS Reimbursement Codes Received in Germany and SwitzerlandPRICE SENSITIVE01/10/13
GIDClinical Research Presented at European Diabetes Meeting26/09/13
GIDEndoBarrier Therapy Clinical Highlights and Activities17/09/13
GIDUpdate on Progress of the ENDO TrialPRICE SENSITIVE12/09/13
GIDAppendix 3B11/09/13
GIDAssociation of British Clinical Diabetologists Funds StudyPRICE SENSITIVE09/09/13
GIDHalf Yearly Report and AccountsPRICE SENSITIVE30/08/13
GID Trading Halt
05/03/15PRICE SENSITIVE
GID Preliminary Final Report
27/02/15PRICE SENSITIVE
GID Appendix 3B
11/02/15
GID Executive Separation Agreement
03/02/15
GID Appendix 4C - quarterly
30/01/15PRICE SENSITIVE
GID Appendix 3B
19/01/15
GID Corporate Restructuring and Departure of CFO
09/12/14PRICE SENSITIVE
GID GI Dynamics Resumes Shipments of EndoBarrier Product
01/12/14PRICE SENSITIVE
GID GI Dynamics to Present at the Piper Jaffray Healthcare Conf
19/11/14
GID Appendix 3B
14/11/14
GID Registration Statement on Form S-8 Filed with SEC
13/11/14
GID Results of Special Meeting of Stockholders
12/11/14
GID Form 10-Q Filed for 3rd Quarter 2014 with SEC
11/11/14PRICE SENSITIVE
GID Final Director's Interest Notice
05/11/14
GID Director Appointment/Resignation
05/11/14
GID Change of Director's Interest Notice
31/10/14
GID Appendix 4C - quarterly
31/10/14PRICE SENSITIVE
GID Notice of Extraordinary General Meeting/Proxy Form
30/10/14
GID Application for Listing on NASDAQ Capital Market
28/10/14
GID Briefing Call and Webcast on Financial Results for Q3 2014
28/10/14
GID Notice of Extraordinary General Meeting/Proxy Form
23/10/14
GID +Change in substantial holding from HHL
14/10/14
GID GI Dynamics Suspends Shipments of CE Marked Product
06/10/14PRICE SENSITIVE
GID Trading Halt
06/10/14PRICE SENSITIVE
GID Initial Director's Interest Notice
19/09/14
GID Appendix 3B
19/09/14
GID New Clinical Data on EndoBarrier Therapy Presented at EASD
18/09/14PRICE SENSITIVE
GID Appendix 3B
17/09/14
GID Change of Director's Interest Notice
15/09/14
GID Initial Director's Interest Notice
12/09/14
GID GI Dynamics Appoints Daniel Moore to the Board of Directors
11/09/14
GID Clinical Data on EndoBarrier Therapy to be Presented at EASD
09/09/14
GID New Clinical Data on EndoBarrier Therapy Presented at IFSO
29/08/14
GID Appointment of Michael Dale as President & CEO
29/08/14PRICE SENSITIVE
GID Half Yearly Report and Accounts
15/08/14PRICE SENSITIVE
GID Appendix 3B
14/08/14
GID +Change in substantial holding from HHL
07/08/14
GID Appendix 4C - quarterly
31/07/14PRICE SENSITIVE
GID Launch of EndoBarrier Therapy Clinical Study in France
30/07/14PRICE SENSITIVE
GID Effectiveness of U.S. SEC Form 10 Registration Statement
21/07/14
GID Briefing Call and Webcast on Financial Results for Q2 2014
21/07/14
GID Appendix 3B
10/07/14
GID Departure of CCO & Update on 2nd Quarter Revenues
02/07/14PRICE SENSITIVE
GID +Becoming a substantial holder from HHL - corrected
20/06/14
GID +Becoming a substantial holder from HHL
19/06/14
GID New EndoBarrier data presented at ADA meeting
16/06/14PRICE SENSITIVE
GID New EndoBarrier data to be presented at ADA meeting
10/06/14
GIDChange of Director's Interest Notice
04/06/14
GIDAppendix 3B
04/06/14
GIDResults of Meeting
22/05/14
GIDAnnual General Meeting - Withdrawal of Resolution 3
20/05/14
GIDReduced Reliance on Insulin by Patients with EndoBarrier
16/05/14PRICE SENSITIVE
GID2014 Annual Meeting of Stockholders Webcast and Call
15/05/14
GIDBecoming a substantial holder - CORRECTION
13/05/14
GIDBecoming a substantial holder
13/05/14
GIDCeasing to be a substantial holder - CORRECTION
12/05/14
GIDTwo New Centres Offer EndoBarrier in Australia
12/05/14
GIDForm604 Notice of change of interests of substantial holder
12/05/14
GIDCeasing to be a substantial holder
09/05/14
GIDChange in substantial holding
09/05/14
GIDChange in substantial holding
09/05/14
GIDChange in substantial holding
09/05/14
GIDChange in substantial holding
09/05/14
GIDASX 3.10.5A announcement
09/05/14
GIDCleansing Notice
09/05/14
GIDAppendix 3B
09/05/14
GIDEndoBarrier Data from Research with GSK Presented at DDW
06/05/14PRICE SENSITIVE
GIDGI Dynamics Completes A$34.3 Million Private Placement
02/05/14PRICE SENSITIVE
GIDGI Dynamics to Present at the Deutsche Bank Healthcare Conf
01/05/14
GIDForm 10 Filed with U.S. Securities and Exchange Commission
01/05/14
GIDNotice of Annual General Meeting/Proxy Form
30/04/14
GIDTrading Halt
30/04/14PRICE SENSITIVE
GIDAppendix 4C - quarterly
29/04/14PRICE SENSITIVE
GIDNew EndoBarrier Data to be Presented at Medical Meetings
29/04/14
GIDBriefing Call and Webcast on Financial Results for Q1 2014
15/04/14
GIDEndoBarrier Receives Reimbursement Coverage in Israel
07/04/14PRICE SENSITIVE
GIDExpands Availability of EndoBarrier Therapy in Australia
01/04/14PRICE SENSITIVE
GIDAnnual Report to shareholders
31/03/14
GIDAppendix 3B
27/03/14
GIDPreliminary Reimbursement Coverage in the Netherlands
27/03/14PRICE SENSITIVE
GIDAppendix 3B
21/03/14
GIDAppendix 3B
12/03/14
AAI +S&P DJ Indices Announces March Quarterly Rebalance
07/03/14
GIDPreliminary Final Report
28/02/14PRICE SENSITIVE
GIDAppendix 3B
04/02/14
GIDExpanded Reimbursement Coverage in Germany
03/02/14PRICE SENSITIVE
GIDAppendix 4C - quarterly
31/01/14PRICE SENSITIVE
GIDBriefing Call and Webcast on Financial Results for Q4 2013
21/01/14
GIDNew Meta-Analysis Further Demonstrates Safety and Efficacy
03/12/13PRICE SENSITIVE
GIDAppendix 3B
20/11/13
GIDAppendix 4C - quarterly
31/10/13PRICE SENSITIVE
GIDChange in substantial holding
29/10/13
GIDAppendix 3B
17/10/13
GIDOPS Reimbursement Codes Received in Germany and Switzerland
01/10/13PRICE SENSITIVE
GIDClinical Research Presented at European Diabetes Meeting
26/09/13
GIDEndoBarrier Therapy Clinical Highlights and Activities
17/09/13
GIDUpdate on Progress of the ENDO Trial
12/09/13PRICE SENSITIVE
GIDAppendix 3B
11/09/13
GIDAssociation of British Clinical Diabetologists Funds Study
09/09/13PRICE SENSITIVE
GIDHalf Yearly Report and Accounts
30/08/13PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

Blue Star Helium (ASX:BNL) has won approval from Colorado regulators to drill five fresh helium wells at its flagship.
NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play Empire Energy (ASX:EEG) has confirmed the NT government has delivered environmental approvals for Carpentaria.
Cyclone signs MOU with Vale for development of Iron Bear play Cyclone Metals Lt has signed a Memorandum of Understanding with Vale S.A to support development of the former's iron ore project in Canada
InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
Banshee's historic trenches prove rich in antimony and gold for GDM Great Divide Mining Ltd has found high-grade antimony and gold through geochemical sampling at its Banshee prospect in Queensland
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.